Pioglitazone - Article Actos
Article: Pioglitazone
 | |
| Pioglitazone | |
| Systematic (IUPAC) name | |
| 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy)phenyl)methyl)-,(+-)- 2,4-thiazolidinedione, | |
| Identifiers | |
| CAS number | 111025-46-8 |
| ATC code | A10BG03 |
| PubChem | 4829 |
| DrugBank | APRD00653 |
| Chemical data | |
| Formula | C19H20N2O3S |
| Mol. weight | 356.44 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | > 99% |
| Metabolism | ? |
| Half life | 3-7 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
In medicine and pharmacology, pioglitazone is a member of the drug class of the thiazolidinediones.
It is being marketed as Actos® by the pharmaceutical companies Takeda and Eli Lilly.
Like other thiazolidinediones, its mechanism of action is by activation the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ.
Side-effects and contraindications
- See main article: thiazolidinedione
See also
- Anti-diabetic drugs
- Peroxisome proliferator-activated receptor
Resources
- Actos (Drug Digest)
- Actos Consumer Information (U.S. Food and Drug Administration)